TT-173

DRUG3 trials

Sponsors

Thrombotargets Europe S.L

Conditions

BurnsDegenerative OsteoarthritisTooth ExtractionTraumatic Lesions

Phase 1

Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction

CompletedNCT01595360

Thrombotargets Europe S.LTooth Extraction

Start: 2012-04-30End: 2013-09-30Updated: 2013-09-16

Phase 2

Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting

CompletedNCT02012569

Thrombotargets Europe S.LBurns, Traumatic Lesions

Start: 2013-11-30End: 2015-07-31Updated: 2016-04-22

Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT)

Thrombotargets Europe S.LDegenerative Osteoarthritis

Start: 2016-01-31End: 2018-12-31Target: 210Updated: 2018-02-22

Related Papers

HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty.

2017-07-041 citations